Bristol-Myers Squibb (BMY) Says EMA Validated its Type II Variation Application for Opdivo Plus Yervoy Combination for Treatment of First-Line Metastatic NSCLC
Tweet Send to a Friend
Bristol-Myers Squibb Company (NYSE: BMY) today announced that the European Medicines Agency (EMA) validated a type II variation application for ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
